Publication at Faculty of Medicine in Pilsen |
2014
Abstract
The targeted therapy improved the prognosis of patients with NSCLC. The new target of treatment includes the ROS1 gene translocation.
Probably, the first case of finding of this translocation in a Czech patient is discussed in our case report. Tyrosine kinase inhibitors for ROS1 are intensively investigated.
The most advanced successful results are shown in recently publicated study phase I with crizotinib. Relating to the similarity with the known ALK translocation we can expected very good efficacy of pemetrex in these indications as well.